School of Medicine
Showing 11-20 of 29 Results
Iris C. Gibbs, MD, FACR, FASTRO
Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery at the Stanford University Medical Center
Current Research and Scholarly Interests Dr. Gibbs is a board-certified radiation oncologist who specializes in the treatment of CNS tumors. Her research focuses on developing new radiation techniques to manage brain and spinal tumors in adults and children. Dr. Gibbs has gained worldwide acclaim for her expertise in Cyberknife robotic radiosurgery.
Kathryn Simmons Stamey Professor
Current Research and Scholarly Interests Benign Prostatic Hyperplasia- Evaluation and development of new minimally invasive techniques
Endourology: developing, designing and evaluating new instruments
Bladder cancer: outcomes of treatment
BPH: cryotherapy and HIFU
Professor of Radiology (Radiological Sciences Lab) and, by courtesy, of Psychology and of Electrical Engineering
Current Research and Scholarly Interests My present research is devoted to the advancement of functional magnetic resonance imaging sciences for applications in basic understanding of the brain in health and disease. We collaborate closely with departmental clinicians and with others in the school of medicine, humanities, and the engineering sciences.
Postdoctoral Research Fellow, Stanford Cancer Center
Bio Zinaida Good, Ph.D. is a 2020 Stanford Cancer Institute Fellow training with Profs. Crystal L. Mackall, M.D. and Sylvia K. Plevritis, Ph.D. at Stanford University. Dr. Good?s research is focused on investigating how chimeric antigen receptor (CAR)-expressing T lymphocytes succeed or fail in patients, in order to guide the design of the next generation of engineered cell therapies. Leveraging multimodal single-cell data analysis, tumor microenvironment imaging, and data integration, she aims to identify features of optimal CAR T cells from patient data. Her projects include: (1) identification of CAR T-cell populations that are associated with durable complete response in diffuse large B-cell lymphoma (DLBCL) patients receiving a CD19-targeted therapy Axicabtagene ciloleucel; (2) defining features of successful CAR T-cell clones in DLBCL patients receiving bispecific CD19/CD22-targeted CAR T cells on a Stanford trial; and (3) identifying modulation points to improve CAR T-cell function within the tumor microenvironment in DLBCL and solid tumors. Dr. Good earned her Ph.D. in Computational & Systems Immunology from Stanford University in April 2018, where she trained with Profs. Garry P. Nolan, Ph.D. and Sean C. Bendall, Ph.D. Her background is in immunology (B.S. and M.S. from the University of British Columbia in Vancouver, Canada) and oncology (she worked for 2 years in Discovery Oncology at Genentech). As a result of her academic training and work experiences, Dr. Good became an inventor on 2 patent applications, co-authored 7 papers, and wrote 3 first-author manuscripts (Good and Sarno et al. Nature Medicine, 2018; Good et al. Nature Biotechnology, 2019; Good et al. Trends in Immunology, 2019). Her long-term interest is in the systems-level events required for a coordinated immune attack against cancer.
Professor of Epidemiology and Medicine (Primary Care and Population Health)
Current Research and Scholarly Interests I am interested in issues relating to the representation and measurement of evidence in medical research, and determinants of the truth of medical findings, using a Bayesian framework. I also do work in evidence synthesis, comparative effectiveness research, and the ethics of clinical research.
Professor of Medicine (Hematology) at the Stanford University Medical Center
Current Research and Scholarly Interests My research interests include phase I/II clinical trial evaluation of novel therapies for the following diseases:
--Myelodysplastic syndromes (MDS)
--Chronic myelogenous leukemia (CML)
--Acute myelogenous leukemia (AML)
--Myeloproliferative disorders (MPDs) including:
Dr. Morris Herzstein Professor of Biology
Current Research and Scholarly Interests We study the molecular mechanisms by which chromatin-signaling networks effect nuclear and epigenetic programs, and how dysregulation of these pathways leads to disease. Our work centers on the biology of lysine methylation, a principal chromatin-regulatory mechanism that directs epigenetic processes. We study how lysine methylation events are generated, sensed, and transduced, and how these chemical marks integrate with other nuclear signaling systems to govern diverse cellular functions.
Gerald Grant, MD, FACS
Endowed Professor in Pediatric Neurosurgery and Professor, by courtesy, of Neurology at the Stanford University Medical Center
Current Research and Scholarly Interests Dr. Grant directs a Blood-brain Barrier Translational Laboratory focusing on enhancing drug delivery to brain tumors in children.
Associate Professor of Pathology at the Stanford University Medical Center
Current Research and Scholarly Interests I have research interests in the interaction of hematolymphoid neoplasia with the microenvironment. For example, I use a combination of immunohistochemistry, immunofluorescence and image analysis techniques to evaluate the mesenchymal stromal cell compartment in myelodysplastic syndrome (pre-leukemic bone marrow failure disorder). I also have interests in lymphoma vasculature and the tropism of lymphoma for specific types of vasculature.
Associate Professor of Radiation Oncology (Radiation Physics) and, by courtesy, of Radiology (Molecular Imaging Program at Stanford)
Current Research and Scholarly Interests Applications of molecular imaging in radiation therapy, development of hypoxia and radiosensitivity imaging techniques, small animal image-guided conformal radiotherapy, image processing and analysis.